Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for NLRP3 Inflammasome Inhibition in COVID-19
NCT04409522Unknown
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of melatonin in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Melatonin at 10 days. Status: unknown.
02
Drugs
melatonin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04409522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409522.